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Edited by Michael R. BubbAbstract This study evaluates whether cardiac ischemia in-
duces release of urocortin, before and independently from myo-
cyte cell death. Urocortin levels rose after 5-min ischemia and
peaked after 10-min ischemia, when cell death was not detected.
However, myocyte apoptosis and/or necrosis occurred following
20- and 30-min ischemia, which paralleled a fall in urocortin lev-
els, suggesting that urocortin expression and release are mainly
sustained by metabolically challenged, though still viable myo-
cytes. Hence, since cardiac release of urocortin, unlike that of
conventional biomarkers, occurs before and apart from cell
death, urocortin levels may be clinically useful in the diagnosis
of sublethal myocardial ischemia.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Urocortin1. Introduction
Urocortin, urocortin II and urocortin III are homologous
peptides related to corticotropin releasing hormone (CRH)
that have all been shown to have potent cardioprotective prop-
erties against ischemia/reperfusion (I/R) injury [1]. There are
two G-protein-coupled receptors for this family, CRH-R1
and CRH-R2, both of which can be expressed as alternatively
spliced forms. Urocortin binds to both receptor subtypes
(though with higher affinity to CRH-R2), while urocortins II
and III are specific for CRH-R2 [1].
The protective effects of urocortin are mediated by a variety
of mechanisms. For example, urocortin activates both the PI3-
kinase/Akt and p42/p44 MAPK signal transduction pathways
[2,3]. Many of the downstream protective mechanisms con-
verge on mitochondria, organelles whose function is severely*Corresponding author. Fax: +44 207 905 2301.
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doi:10.1016/j.febslet.2008.02.035compromised by I/R, leading to both apoptotic and necrotic
cell death [4]. Thus, urocortin increases mitochondrial expres-
sion and activity of the Kir6.1 KATP channel [5], causes trans-
location of PKCe to the mitochondrial membrane [6] and
reduces the levels of iPLA2 and its toxic metabolite, LPC, in
mitochondria [7].
Cardiac myocytes express urocortin, urocortin II and uro-
cortin III together with one spliced isoform of CRH-R2,
depending on species [1]. This suggests that endogenous uro-
cortins may also act via an autocrine/paracrine cardioprotec-
tive mechanism. Indeed, supernatants from primary cultures
of rat cardiomyocytes exposed to I/R are cardioprotective
and these cardioprotective effects of ischemia-preconditioned
media are inhibited by CRH-R antagonists [8]. In addition,
we have shown that both myocyte apoptosis and urocortin
expression are increased in human hearts exposed to cardiople-
gic arrest, a common iatrogenic form of I/R, and all urocortin
positive cells are viable, while apoptotic cells are urocortin-
negative [9]. Moreover, urocortin-positive myocytes are sur-
rounded by a cuff of viable urocortin-negative cells which,
however, express the Kir6.1 ATP-dependent potassium chan-
nel, whose opening has been implicated in urocortin-mediated
cardioprotection. Since we previously showed that urocortin
induced Kir6.1 overexpression in the rat heart [5], this finding
seems to corroborate the hypothesis that autocrine/paracrine
enhancement of KATP channel expression by endogenously-re-
leased urocortin is also one mechanism of its cardioprotective
function in the human heart.
The evaluation of patients with chest pain is often challeng-
ing and may be misleading [10]. The incorrect diagnosis of
acute cardiac ischemia, with subsequent admission to costly
emergency and observation units, incurs redundant expenses.
On the other hand, the misinterpretation of cardiac chest pain,
with discharge of patients with acute myocardial infarction,
considerably increases the risk of adverse outcomes. The recent
development and characterization of precise imaging tech-
niques, as well as analytically dependable biomarkers to con-
firm or exclude cardiac ischemia, has certainly refined the
diagnosis of acute myocardial infarction, but only limitedly
facilitated the diagnosis of coronary events due to transientblished by Elsevier B.V. All rights reserved.
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patients are often admitted to the hospital only after the remis-
sion of their symptoms, and therefore exhibit at the same time
negative necrosis biomarkers and a normalized EKG trace.
As previously stated, urocortin is a cardioprotective peptide,
which is released by cardiac cells exposed to I/R injury. Hence,
based on these premises, we have assessed whether myocyte
release of urocortin is merely a local event, or whether myo-
cyte-derived urocortin is also released systemically and could
therefore act as a circulating biomarker for I/R injury. Hence,
we have assayed urocortin in the perfusate of Langendorff-per-Table 1
Overview of the different time points of I/R, used for the ex vivo and in viv
Ex vivo ischemia/reperfusion
Control hearts (6 units)
Stabilization (10 m)
I/R groups (6 units per group)
Stabilization (10 m) 5 m zero-flow globa
Stabilization (10 m) 10 m zero-flow glob
Stabilization (10 m) 20 m zero-flow glob
Stabilization (10 m) 30 m zero-flow glob
In vivo ischemia/reperfusion
Control hearts (6 units)
Open thoracotomy for 2 h
I/R groups (6 units per group)
5 m regional ischemia
10 m regional ischemia
20 m regional ischemia
30 m regional ischemia
Fig. 1. Four adjacent myocardial sections serially cut from the same iso
myocytes, as identified by the ‘‘red banding’’ running perpendicularly to th
urocortin mRNA and protein. White arrows indicate urocortin-positiv
counterstained with propidium iodide (orange nuclei), no cell shows TUNEL
Magnification: 400·.fused Sprague–Dawley rat hearts exposed to increasing periods
of zero-flow global ischemia followed by reperfusion, as well as
in the circulation of Sprague–Dawley rats exposed in vivo to
identical periods of regional ischemia and reperfusion.2. Materials and methods
2.1. Ex vivo ischemia/reperfusion
Isolated Langendorff-perfused hearts from adult male Sprague–
Dawley rats were exposed to I/R and their mechanical function was
monitored, as described previously [12]. At least six hearts were usedo sets of experiments
Simple perfusion (2 h)
l ischemia 2 h reperfusion
al ischemia 2 h reperfusion
al ischemia 2 h reperfusion






lated Langendorff-perfused control heart. (Panel a) Desmin-positive
eir long axis. (Panels b and c) Same myocyte population stained for
e myocytes. (Panel d) Among the matching myocyte population
-positive staining (for details of TUNEL positive labeling see Fig. 5d).
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group was simply perfused with Krebs–Heinsleit buffer for 2 h, while
the treated groups were exposed to 5, 10, 20 or 30 min of zero-flow glo-
bal ischemia and subsequently to 2 h reperfusion (Table 1).
2.2. Immunohistochemistry, fluorescent in situ hybridization, and
TUNEL staining
Four adjacent 4 lm myocardial sections were serially cut from the
same wax blocks of each group, and stained with either an anti-desmin
antibody (used as a marker of cardiac cells), or an antisense urocortin
cRNA probe synthesized with a 3 0-biotinylated tail, or an anti-urocor-
tin antibody, or a fluorescein-conjugated TUNEL labeling, with propi-
dium iodide used as a counterstaining [9,13,14]. The urocortin probe
consisted of 48 bases (AAA-TAA-CCA-CTC-AGA-GTA-TTC-
AGG-GTG-ACT-CTG-GGC-GCG-CTG-CAC-CGC) and was
complementary to the rat mRNA encoding base pairs 571–618 of
the urocortin message (GenBank accession number NM021290).
A rhodamine-conjugated secondary antibody was used to label des-
min, while Cy5-conjugated streptavidin and a fluorescein-conjugated
secondary antibody were used to label urocortin messenger and pro-
tein, respectively. Sections were finally analyzed by confocal fluores-
cent microscopy. Data were expressed as the means of 12–15 high
power fields, ±S.D.
2.3. In vivo ischemia/reperfusion
Adult male Sprague–Dawley rats were anesthetised, ventilated using
room air through a tracheotomy, and exposed to thoracotomy crossing
the fifth intercostal space [15]. At least six rats were used in each group.
In control sham-operated animals, the surgical breach was kept patentTable 2





Control hearts 15 ± 2.5%
5-min ischemia + 2 h reperfusion 41 ± 4.2**
10-min ischemia + 2 h reperfusion 58 ± 6.8**
20-min ischemia + 2 h reperfusion 22 ± 1.4*
30-min ischemia + 2 h reperfusion 20 + 3.7%*
* P < 0.05.
** P < 0.01, versus control hearts.
Fig. 2. Concentration of urocortin (Panel a) and CPK (Panel b) in the per
(for explanation see Section 2).for 2 h, before being sutured. In treated animals, the left coronary ar-
tery was occluded for 5, 10, 20 or 30 min and subsequently reperfused
for 2 h (Table 1).
2.4. Urocortin and creatine phosphokinase (CPK) assays
Urocortin concentrations were evaluated by competitive radioimmu-
noassay [16], using a commercially available kit (Phoenix Pharmaceu-
tical; sensitivity range: from 0.2 to 27 pmol/L), according to the
recommended protocol, while CPK levels were evaluated spectropho-
tometrically [12]. For the ex vivo groups, the perfusate was collected
from the control hearts before (after stabilization) and after the buffer
perfusion, and from the treated hearts before ischemia (after stabiliza-
tion) and after reperfusion. For the in vivo groups, 1 ml of blood was
collected from the tail vein of both sham-operated and treated rats be-
fore the execution of the thoracotomy and after the closure of the tho-
racotomy breach.
The Langendorff perfusate was collected in chilled glass and subse-
quently concentrated by means of a centrifugal concentrator (Speed-
Vac). Blood samples were collected into Lavender Vacutainer tubes,
containing EDTA, transferred into centrifuge tubes containing aproti-
nin and subsequently centrifuged at 1600 · g for 15 min, to allow col-
lection of plasma. Peptide extraction from collected perfusate and
plasma was completed by means of pre-treated C18 separation col-
umns, before measurement by competitive radioimmunoassay.
2.5. Statistics
Comparisons between different groups were made using repeated
measures two-way ANOVA with appropriate post-doc analysis: P-val-





12 ± 2.2% <0.1
35 ± 3.8** <0.1
52 ± 6.2** <0.1
24 ± 1.8* 6.3 + 1.2**
18 ± 3.2* 8.9 ± 2.3%**
fusate from isolated Langendorff-perfused control and treated hearts
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In serial adjacent sections from control hearts unexposed to
I/R, among the population of desmin-positive myocytes
(Fig. 1a), only a small percentage (Table 2) expressed urocortin
at the mRNA (Fig. 1b) and protein level (Fig. 1c), and none
showed evidence of apoptosis, as assessed by TUNEL staining
(Fig. 1d). Furthermore, no urocortin (Fig. 2a) or CPK
(Fig. 2b) were released in the perfusate from the same control
hearts, either before or after perfusion. Hence, control hearts
showed low basal expression of urocortin, no release of uro-
cortin in the perfusate and absence of both apoptosis and
necrosis. Conversely, a significantly increased proportion of
desmin-positive cardiomyocytes (Fig. 3a) from hearts exposed
to 5- and 10-min ischemia showed enhanced expression of uro-
cortin (Table 2) at the mRNA (Fig. 3b) and protein (Fig. 3c)
level, although none of them were apoptotic (Fig. 3d). In these
two groups, urocortin was also released into the perfusate after
reperfusion in amounts proportional to the duration of ische-
mia (Fig. 2a). More specifically, perfusate urocortin levels,
which were undetectable at the end of stabilization, signifi-
cantly rose in hearts receiving 5-min ischemia (13.6 ±
0.7 pmol/L), and almost doubled following 10-min ischemia,
reaching a mean concentration of 24.86 ± 1.3 pmol/L (both
P-values <0.001, versus control). However, no significant re-
lease of CPK into the perfusate was seen from these hearts
(Fig. 2b), exhibiting a complete hemodynamic recovery follow-
ing ischemia (Fig. 4a and b). Hence, in heart exposed to shortFig. 3. Four adjacent myocardial sections serially cut from the same isola
reperfusion. (Panel a) Desmin-positive myocytes with identifying ‘‘red band
expression (white arrows) of urocortin mRNA and protein, as compared to
with propidium iodide (orange nuclei), lacking TUNEL-positive staining
Magnification: 400·.ischemia, increased transcription, translation and release of
urocortin were associated with neither apoptotic nor necrotic
cell death.
With longer periods of ischemia (20 and 30 min) followed
again by a 2 h reperfusion period, the proportion of desmin-
positive myocytes (Fig. 5a) overexpressing urocortin mRNA
(Fig. 5b) and protein (Fig. 5c) fell dramatically and propor-
tionally to the length of ischemia (Table 2). Moreover, in the
same myocyte population, indeed TUNEL-positive nuclear
staining (Fig. 5d) was observed (Table 2), and, of note, all
myocytes undergoing apoptosis were negative for urocortin
mRNA (Fig. 5b) as well as for urocortin protein (Fig. 5c). In
line with this finding, cardiac release of urocortin in the perfus-
ate from hearts exposed to 20 and 30 min of ischemia was also
significantly reduced (Fig. 2a), while that of CPK was dramat-
ically heightened (Fig. 2b), which paralleled a significant
impairment of postischemic recovery of cardiac function
(Fig. 4c and d). The reduced transcription and translation of
urocortin in viable myocytes, the exclusive occurrence of
apoptosis in urocortin-negative cardiac cells, and the pattern
of cardiac release of urocortin, which, in correlation with
postischemic recovery of cardiac function, diminishes with
increasing ischemic times, unlike that of CKP, which progres-
sively augments, suggest that cardiac expression and release of
urocortin are mainly sustained by metabolically challenged,
but still viable myocytes.
To assess whether a similar pattern of cardiac release of uro-
cortin into the circulation could also be observed followingted Langendorff-perfused heart exposed to 10-min ischemia and 2 h
ing’’. (Panels b and c) Same myocyte population showing enhanced
control hearts. (Panel d) Matching myocyte population counterstained
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Fig. 4. Recovery of left ventricular developed pressure (LVDP) in the isolated Langendorff-perfused rat heart exposed to 5- (Panel a), 10- (Panel b),
20- (Panel c) and 30 (Panel d)-min ischemia, followed by 2 h reperfusion.
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exposed to either 5, 10, 20 or 30 min of in vivo regional ische-
mia, followed by 2 h reperfusion. In parallel with the ex vivo
studies, urocortin plasma levels, assessed after the closure of
the thoracotomy, were significantly higher in the rats subjected
to short ischemia (5 and 10 min, Fig. 6a; all P-values <0.05
versus controls), whose groups showed no elevation of CPK
plasma levels, as compared to sham-operated animals
(Fig. 6b; P-values <0.05, versus sham-operated controls, only
for groups given 20- and 30-min ischemia).4. Discussion
Although basal urocortin levels were previously reported to
be around 14 and 20 pmol/L in normal females and males,
respectively [17], in our study, perfusate and plasma urocortin
concentrations were below the limits of assay detection. This
apparent discrepancy might be explained with differences in
heart mass between diverse species. Moreover, plasma urocor-
tin levels, which were significantly increased in patients with
heart failure, especially in its early stages, increasingly fell with
progression of the disease [17]. This drop in concentration par-alleled a significant correlation between urocortin levels and
values of ejection fraction, a powerful indicator of cardiac
function, suggesting that cardiac release of urocortin is mainly
achieved by functionally competent, rather than dysfunctional,
cardiac myocytes.
In our previous study, we documented that the mild, though
metabolically challenging, form of ischemia iatrogenically
given to the human heart during cardioplegic arrest, is ‘‘per
se’’ sufficient to induce increased cardiac expression and poten-
tially release of urocortin. This was confirmed in the present
study, where urocortin was detected in the perfusate and the
plasma of rats exposed to ex vivo and in vivo I/R injury,
respectively. The absence of urocortin from the plasma of
sham-operated rats, both before the execution of the thoracot-
omy and after the closure of the thoracotomy breach, suggests
that neither anesthesia nor surgery alone increase circulating
urocortin levels, although small but significant rises in plasma
CRH have been reported in patients undergoing cholecystec-
tomy [18].
The highest release of urocortin into both perfusate and
plasma was seen with 5- and 10-min ischemia, when the post-
ischemic functional recovery was complete and there was nei-
ther myocyte apoptosis nor release of conventional markers
Fig. 5. Four adjacent myocardial sections serially cut from the same isolated Langendorff-perfused heart exposed to 30-min ischemia and 2 h
reperfusion. (Panel a): Desmin-positive myocytes with typical ‘‘red banding’’. (Panels b and c) Same myocyte population showing reduced expression
(white arrows) of urocortin mRNA and protein, as compared to hearts exposed to short ischemia. (Panel d) Matching myocyte population
counterstained with propidium iodide (orange nuclei), showing nuclear TUNEL-positive staining (yellow nuclei pointed by white arrows).
Magnification: 400·.
Fig. 6. Plasma concentration of urocortin (Panel a) and CPK (Panel b) in sham-operated and treated rats exposed to in vivo I/R injury
(for explanation see Section 2).
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mal data presented in this study are preliminary and need
extensive confirmation in the clinical setting, measurement of
serum urocortin may be a potentially useful and relatively
inexpensive biochemical indicator of mild sublethal ischemia,
where significant myocyte loss has not occurred. In particular,
it may be valuable in the differential diagnosis of brief episodesof chest pain, especially when other specific, but later, clinical
parameters of cardiac injury, such as CPK and ECG changes
are negative. Similarly, during cardiac surgery, the measure-
ment of serum urocortin may help in the identification of peri-
and post-operative cardiac injury. In particular, serum urocor-
tin may be a more specific marker of ischemic injury, since the
elevation of other current biochemical markers, such as
990 R.A. Knight et al. / FEBS Letters 582 (2008) 984–990cardiac troponin and CPK, may be a consequence of iatro-
genic injury from the surgery itself, whereas serum urocortin
is unaffected either by anaesthesia or surgery.
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